96 results on '"Zielinski C"'
Search Results
2. TIME TO TREAT THE CLIMATE AND NATURE CRISIS AS ONE INDIVISIBLE GLOBAL HEALTH EMERGENCY.
- Author
-
Abbasi, K., Ali, P., Barbour, V., Benfield, T., Bibbins-Domingo, K., Hancocks, S., Horton, R., Laybourn-Langton, L., Mash, R., Sahni, P., Sharief, W. M., Shehab, A., Yonga, P., and Zielinski, C.
- Subjects
GREENHOUSE gases ,WORLD health ,PUBLIC health ,CONFERENCES & conventions ,MEDICAL emergencies ,ENVIRONMENTAL health ,ECOSYSTEMS ,URBANIZATION ,CLIMATE change - Abstract
The article focuses on urging global recognition that climate change and biodiversity loss constitute an indivisible crisis requiring unified action to preserve health and avert catastrophe. It reports the dangerous misconception of treating climate and nature crises separately, and it emphasizes the need for integrated solutions, as the interdependent natural world faces severe damage, threatening human health and exacerbating social and economic challenges.
- Published
- 2023
3. Time to treat the climate and nature crisis as one indivisible global health emergency.
- Author
-
Abbasi, K., Ali, P., Barbour, V., Benfield, T., Bibbins‐Domingo, K., Hancocks, S., Horton, R., Laybourn‐Langton, L., Mash, R., Sahni, P, Sharief, W. M., Yonga, P., and Zielinski, C.
- Subjects
CLIMATE change ,WORLD health ,INDIGENOUS Australians ,ENVIRONMENTAL research - Abstract
Over 200 health journals have issued a joint statement calling on the United Nations, political leaders, and health professionals to recognize that climate change and biodiversity loss are interconnected crises that must be addressed together. The statement emphasizes that the current approach of treating these issues separately is a dangerous mistake. The impacts of these crises on human health are significant and include disruptions to social and economic systems, shortages of land, shelter, food, and water, and the spread of infectious diseases. The health community must advocate for the restoration of biodiversity and the mitigation of climate change, and political leaders must recognize the threats to health and the potential benefits of addressing these crises. The statement concludes by urging the World Health Organization to declare the climate and nature crisis as a global health emergency. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
4. Time to treat the climate and nature crisis as one indivisible global health emergency.
- Author
-
Abbasi, K., Ali, P., Barbour, V., Benfield, T., Bibbins‐Domingo, K., Hancocks, S., Horton, R., Laybourn‐Langton, L., Mash, R., Sahni, P., Sharief, W. M., Yonga, P., and Zielinski, C.
- Subjects
CLIMATE change ,WORLD health ,INDIGENOUS Australians ,LIFE sciences ,ENVIRONMENTAL research - Abstract
Over 200 health journals have issued a joint statement calling on the United Nations, political leaders, and health professionals to recognize that climate change and biodiversity loss are interconnected crises that must be addressed together. The statement emphasizes that the current approach of treating these issues separately is a dangerous mistake. The impacts of these crises on human health are significant and include disruptions to social and economic systems, shortages of land, shelter, food, and water, and the spread of infectious diseases. The health community must advocate for the restoration of biodiversity and the mitigation of climate change, and political leaders must recognize the severe threats to health and the potential benefits of addressing these crises. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
5. Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center.
- Author
-
Füreder, L. M., Widhalm, G., Gatterbauer, B., Dieckmann, K., Hainfellner, J. A., Bartsch, R., Zielinski, C. C., Preusser, M., and Berghoff, A. S.
- Abstract
Symptomatic brain metastases (BM) are a frequent and late complication in cancer patients. However, a subgroup of cancer patients presents with BM as the first symptom of metastatic cancer. Here we aimed to analyze the clinical course and prognostic factors of this particular BM patient population. Patients presenting with newly diagnosed BM without a history of metastatic cancer were identified from the Vienna Brain Metastasis Registry. Clinical characteristics and overall survival were retrieved by chart review. 459/2419 (19.0%) BM patients presented with BM as first symptom of advanced cancer. In 374/459 (81.5%) patients, an extracranial primary tumor, most commonly lung cancer, could be identified within 3 months after BM diagnosis. In 85/459 (18.5%) patients no extracranial primary tumor could be identified despite comprehensive diagnostic workup within the first 3 months after diagnosis of BM. Survival of patients with identified extracranial tumor differed only numerically from patients with cancer of unknown primary (CUP), however patients receiving targeted therapy after molecular workup showed significantly enhanced survival (20 months vs. 7 months; p = 0.003; log rank test). The GPA score showed a statistically significant association with median overall survival times in the CUP BM patients (class I: 46 months; class II: 7 months; class III: 4 months; class IV: 2 months; p < 0.001; log rank test). The GPA score has a strong prognostic value in patients with CUP BM and may be useful for patient stratification in the clinical setting. Comprehensive diagnostic workup including advanced imaging techniques and molecular tissue analyses appears to benefit patients by directing specific molecular targeted therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. TH17 cells express ST2 and are controlled by the alarmin IL-33 in the small intestine.
- Author
-
Pascual-Reguant, A, Bayat Sarmadi, J, Baumann, C, Noster, R, Cirera-Salinas, D, Curato, C, Pelczar, P, Huber, S, Zielinski, C E, Löhning, M, Hauser, A E, and Esplugues, E
- Published
- 2017
- Full Text
- View/download PDF
7. Measuring sequences of keystrokes with jsPsych: Reliability of response times and interkeystroke intervals.
- Author
-
Pinet, S., Zielinski, C., Mathôt, S., Dufau, S., Alario, F.-X., and Longcamp, M.
- Subjects
REACTION time ,WEB-based user interfaces ,JAVASCRIPT programming language ,COMPUTER operating systems ,RELIABILITY in engineering - Abstract
Although the precision and reliability of response time (RT) measurements performed via Web-based interfaces have been evaluated, sequences of keystrokes have never been investigated in detail. Keystrokes often occur in much more rapid succession than RTs, and operating systems may interpret successive or concomitant keyboard events according to both automatic and user-based settings. Sequence keystroke timing could thus be more sensitive than single RTs to noise in online measurements. Here, we quantified the precision and reliability of timing measures performed during sequences of keystrokes. We used the JavaScript jsPsych library to create an experiment involving finger-movement sequences, and ran it online with 633 participants. We manipulated the structure of three keystroke motor sequences, targeting a replication of previous findings regarding both RTs and interkeystroke intervals (IKIs). Our online data accurately reproduced the original results and allowed for a novel assessment of demographic variables such as age and gender. In parallel, we also measured the objective timing accuracy of the jsPsych interface by using specialized hardware and software, showing a constant 60-ms delay for RTs and a 0-ms delay for IKIs across the sequences. The distribution of IKIs revealed quantizing for a majority of participants, most likely due to the sampling frequency of their USB keyboards. Overall, these findings indicate that JsPsych provides good reliability and accuracy in sequence keystroke timings for mental chronometry purposes, through online recordings. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
- Author
-
Lamm, W., Willenbacher, W., Lang, A., Zojer, N., Müldür, E., Ludwig, H., Schauer-Stalzer, B., Zielinski, C., Drach, J., Müldür, E, and Zielinski, C C
- Subjects
DEXAMETHASONE ,MULTIPLE myeloma treatment ,AMYLOIDOSIS ,HEMATOLOGIC agents ,DRUG efficacy ,NEUROPATHY ,THERAPEUTIC use of antineoplastic agents ,RESEARCH ,BORON compounds ,HETEROCYCLIC compounds ,RESEARCH methodology ,PROGNOSIS ,ANTINEOPLASTIC agents ,RETROSPECTIVE studies ,EVALUATION research ,MEDICAL cooperation ,TREATMENT effectiveness ,COMPARATIVE studies ,DISEASE remission - Abstract
Bortezomib-dexamethasone (Btz/Dex) is an active regimen in patients with multiple myeloma and has been used in few patients with amyloidosis. Here, we report a retrospective evaluation of the efficacy and toxicity of Btz/Dex in 26 patients with AL amyloidosis (AL). Eighteen patients (69%) received Btz/Dex as first-line treatment. Organs most frequently involved were kidneys (100%) and heart (35%); five patients (19%) had less than two organs involved. The overall response rate was 54% (14 of 26 patients), with eight patients (31%) achieving a hematologic complete remission (CR). All patients who reached a CR received Btz/Dex as first-line therapy. Median time to response was 7.5 weeks. Improvement in organ function was noticed in three patients (12%). Median progression-free survival (PFS) and overall survival (OS) was 5.0 and 18.7 months, respectively; in CR patients, however, median PFS and OS have not yet been reached. Toxicities were manageable, with hematological side effects being most common. No grade 3/4 neuropathy was observed. Our results confirm the activity of bortezomib/dexamethasone in patients with AL amyloidosis and suggest that patients achieving a CR have a marked benefit for survival. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Prognostic impact of breast cancer subtypes in elderly patients.
- Author
-
Bergen, E., Tichy, C., Berghoff, A., Rudas, M., Dubsky, P., Bago-Horvath, Z., Mader, R., Exner, R., Gnant, M., Zielinski, C., Steger, G., Preusser, M., and Bartsch, R.
- Abstract
We aimed to analyse the impact of breast cancer (BC) subtypes on the clinical course of disease with special emphasis on the occurrence of brain metastases (BM) and outcome in an elderly BC population. A total number of 706 patients ≥65 years receiving treatment for BC from 2007 to 2011 were identified from a BC database. 62 patients diagnosed with DCIS and 73 patients with incomplete datasets were excluded, leaving 571 patients for this analysis. Patient characteristics, biological tumour subtypes, and clinical outcome including overall survival (OS) were obtained by retrospective chart review. 380/571 (66, 5 %) patients aged 65-74 years were grouped among the young-old, 182/571 (31.9 %) patients aged 75-84 years among the old-old, and 29/571 (5.1 %) patients aged ≥85 years among the oldest-old. 392/571 (68.8 %) patients presented with luminal BC, 119/571 (20.8 %) with HER2-positive, and 59/571 (10.3 %) with triple-negative BC (TNBC). At 38 months median follow-up, 115/571 (20.1 %) patients presented with distant recurrence. A higher recurrence rate was observed in the HER2-positive subtype (43/119 (36.1 %)), as compared to TNBC (15/59 (25.4 %)) and luminal BC (57/392 (14.5 %); p < 0.001). BM were detected at a significantly higher rate in HER2-positive BC patients (9/119 (7.6 %)), as compared to TNBC (2/59 (3.4 %)) and luminal BC patients (6/392 (1.5 %); p = 0.003). Diagnosis of metastatic disease (HR 7.7; 95 % CI 5.2-11.4; p < 0.001) as well as development of BM (HR 3.5; 95 % CI 1.9-6.4; p < 0.001) had a significantly negative impact on OS in a time-dependent covariate cox regression model. In contrast to younger BC patients, outcome in this large cohort of elderly patients suggests that HER2-positive disease-not TNBC-featured the most aggressive clinical course with the highest rates of metastatic spread and BM. In-depth analysis regarding a potentially distinct biology of TNBC in elderly is therefore warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Abscopal-Effekt in der Therapie des malignen Melanoms.
- Author
-
Thallinger, C., Prager, G., Ringl, H., and Zielinski, C.
- Abstract
Copyright of Der Hautarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2015
- Full Text
- View/download PDF
11. Die Rolle von IL-1β in der Dermatologie.
- Author
-
Reidel, R. U. and Zielinski, C. E.
- Published
- 2015
- Full Text
- View/download PDF
12. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
- Author
-
Brodowicz, T, Lang, I, Kahan, Z, Greil, R, Beslija, S, Stemmer, S M, Kaufman, B, Petruzelka, L, Eniu, A, Anghel, R, Koynov, K, Vrbanec, D, Pienkowski, T, Melichar, B, Spanik, S, Ahlers, S, Messinger, D, Inbar, M J, and Zielinski, C
- Subjects
BREAST cancer treatment ,DRUG efficacy ,ANTINEOPLASTIC agents ,BEVACIZUMAB ,PACLITAXEL ,COMBINATION drug therapy ,COMPARATIVE studies - Abstract
Background:The randomised phase III TURANDOT trial compared first-line bevacizumab-paclitaxel (BEV-PAC) vs bevacizumab-capecitabine (BEV-CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). The interim analysis revealed no difference in overall survival (OS; primary end point) between treatment arms; however, progression-free survival (PFS) and objective response rate were significantly superior with BEV-PAC. We sought to identify patient populations that may be most appropriately treated with one or other regimen.Methods:Patients with HER2-negative LR/mBC who had received no prior chemotherapy for advanced disease were randomised to either BEV-PAC (bevacizumab 10 mg kg
−1 days 1 and 15 plus paclitaxel 90 mg m−2 days 1, 8 and 15 q4w) or BEV-CAP (bevacizumab 15 mg kg−1 day 1 plus capecitabine 1000 mg m−2 bid days 1-14 q3w). The study population was categorised into three cohorts: triple-negative breast cancer (TNBC), high-risk hormone receptor-positive (HR+) and low-risk HR+. High- and low-risk HR+ were defined, respectively, as having ⩾2 vs ⩽1 of the following four risk factors: disease-free interval ⩽24 months; visceral metastases; prior (neo)adjuvant anthracycline and/or taxane; and metastases in ⩾3 organs.Results:The treatment effect on OS differed between cohorts. Non-significant OS trends favoured BEV-PAC in the TNBC cohort and BEV-CAP in the low-risk HR+ cohort. In all three cohorts, there was a non-significant PFS trend favouring BEV-PAC. Grade ⩾3 adverse events were consistently less common with BEV-CAP.Conclusions:A simple risk factor index may help in selecting bevacizumab-containing regimens, balancing outcome, safety profile and patient preference. Final OS results are expected in 2015 (ClinicalTrials.gov NCT00600340). [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
13. Die Rolle von IL-1β in der Dermatologie.
- Author
-
Reidel, R. U. and Zielinski, C. E.
- Published
- 2014
- Full Text
- View/download PDF
14. Generation of linear cartesian trajectories for robots using industrial motion-controllers.
- Author
-
Zielinski, C. and Kornuta, T.
- Published
- 2011
- Full Text
- View/download PDF
15. Behavior-based control system of a robot actively recognizing hand postures.
- Author
-
Kornuta, T. and Zielinski, C.
- Published
- 2011
- Full Text
- View/download PDF
16. Parallel visual-force control.
- Author
-
Staniak, M., Winiarski, T., and Zielinski, C.
- Published
- 2008
- Full Text
- View/download PDF
17. Implementation of position-force control in MRROC++.
- Author
-
Winiarski, T. and Zielinski, C.
- Published
- 2005
- Full Text
- View/download PDF
18. Applications of MRROC++ robot programming framework.
- Author
-
Zielinski, C., Szynkiewicz, W., and Winiarski, T.
- Published
- 2005
- Full Text
- View/download PDF
19. Specification of behavioural embodied agents.
- Author
-
Zielinski, C.
- Published
- 2004
- Full Text
- View/download PDF
20. Reaction to errors in robot systems.
- Author
-
Zielinski, C.
- Published
- 2002
- Full Text
- View/download PDF
21. A quasi-formal approach to structuring multi-robot system controllers.
- Author
-
Zielinski, C.
- Published
- 2001
- Full Text
- View/download PDF
22. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients.
- Author
-
Reitter, E.‐M., Ay, C., Kaider, A., Pirker, R., Zielinski, C., Zlabinger, G., and Pabinger, I.
- Subjects
CANCER patients ,INTERLEUKINS ,THROMBOEMBOLISM ,CYTOKINES ,CANCER invasiveness ,PANCREATIC cancer - Abstract
Cytokines have been found to be elevated in cancer patients and have been associated with worse prognosis in single tumour entities. We investigated the association of eight different cytokines with venous thromboembolism ( VTE) and prognosis in cancer patients. The Vienna Cancer and Thrombosis Study ( CATS), a prospective study, includes patients with newly diagnosed tumour or disease progression. Patients with an overt infection are excluded. Study end-points are VTE, death, loss to follow-up or study completion. Interleukin ( IL) serum levels were measured using the xMAP technology developed by Luminex. Among 726 included patients, no associations between IL levels and VTE were found, with the exception of a trend for IL-1β and IL-6 in pancreatic cancer. Elevated levels of IL-6 [as continuous variable per double increase hazard ratio ( HR) = 1·07, 95% confidence interval ( CI) = 1·027-1·114, P = 0·001, IL-8 ( HR = 1·12, 95% CI = 1·062-1·170, P < 0·001) and IL-11 ( HR = 1·37, 95% CI = 1·103-1·709, P = 0·005] were associated with worse survival. In subgroup analyses based on tumour type, colon carcinoma patients, who had higher IL-6 levels, showed a shorter survival ( HR = 2·405, 95% CI = 1·252-4·618, P = 0·008). A significant association of elevated IL-10 levels with a decrease in survival ( HR = 1·824, 95% CI = 1·098-3·031, P = 0·020) was seen among patients with lung cancer. No correlation between VTE and IL levels was found, but higher IL-6, IL-8 and IL-11 levels were associated with worse survival in cancer patients. Further, elevated IL-6 levels might be a prognostic marker in colorectal cancer and elevated IL-10 levels in lung cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
23. Liver Transplantation in a Patient with Unresectable Colorectal Liver Metastases - A Case Report.
- Author
-
Hrehoreţ, D., Alexandrescu, S., Braşoveanu, V., Grigorie, R., Zielinski, C., and Popescu, I.
- Published
- 2013
24. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors.
- Author
-
Berghoff, A S, Bago-Horvath, Z, Ilhan-Mutlu, A, Magerle, M, Dieckmann, K, Marosi, C, Birner, P, Widhalm, G, Steger, G G, Zielinski, C C, Bartsch, R, and Preusser, M
- Subjects
BRAIN metastasis ,BREAST cancer ,SURVIVAL analysis (Biometry) ,LONG-term care facilities ,ESTROGEN receptors ,PROGESTERONE receptors - Abstract
Background:The clinical course of breast cancer patients with brain metastases (BM) as only metastatic site (brain-only metastatic breast cancer (BO-MBC)) has been insufficiently explored.Methods:All breast cancer patients with BM treated at our institution between 1990 and 2011 were identified. For each patient, full information on follow-up and administered therapies was mandatory for inclusion. Oestrogen receptor, progesterone receptor and Her2 status were determined according to standard protocols. Statistical analyses including computation of survival probabilities was performed.Results:In total, 222 female patients (26% luminal; 47% Her2; 27% triple negative) with BM of MBC were included in this study. In all, 38/222 (17%) BM patients did not develop extracranial metastases (ECM) during their disease course and were classified as BO-MBC. Brain-only-MBC was not associated with breast cancer subtype or number of BM. The median overall survival of BO-MBC patients was 11 months (range 0-69) and was significantly longer than in patients with BM and ECM (6 months, range 0-104; P=0.007). In all, 7/38 (18%) BO-MBC patients had long-term survival of >3 years after diagnosis of BM and long-term survival was significantly more common in BO-MBC patients as compared with BM patients with ECM (P<0.001).Conclusions:Brain-only metastatic behaviour occurs in around 17% of breast cancer with BM and is not associated with breast cancer subtype. Exploitation of all multimodal treatment options is warranted in BO-MBC patients, as these patients have favourable prognosis and long-term survival is not uncommon. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
25. The MRROC++ system.
- Author
-
Zielinski, C.
- Published
- 1999
- Full Text
- View/download PDF
26. Brain metastases free survival differs between breast cancer subtypes.
- Author
-
Berghoff, A, Bago-Horvath, Z, De Vries, C, Dubsky, P, Pluschnig, U, Rudas, M, Rottenfusser, A, Knauer, M, Eiter, H, Fitzal, F, Dieckmann, K, Mader, R M, Gnant, M, Zielinski, C C, Steger, G G, Preusser, M, and Bartsch, R
- Subjects
BRAIN diseases ,METASTASIS ,BREAST cancer patients ,IMMUNOHISTOCHEMISTRY ,FLUORESCENCE in situ hybridization - Abstract
Background:Brain metastases (BM) are frequently diagnosed in patients with HER-2-positive metastatic breast cancer; in addition, an increasing incidence was reported for triple-negative tumours. We aimed to compare brain metastases free survival (BMFS) of breast cancer subtypes in patients treated between 1996 until 2010.Methods:Brain metastases free survival was measured as the interval from diagnosis of extracranial breast cancer metastases until diagnosis of BM. HER-2 status was analysed by immunohistochemistry and reanalysed by fluorescent in situ hybridisation if a score of 2+ was gained. Oestrogen-receptor (ER) and progesterone-receptor (PgR) status was analysed by immunohistochemistry. Brain metastases free survival curves were estimated with the Kaplan-Meier method and compared with the log-rank test.Results:Data of 213 patients (46 luminal/124 HER-2/43 triple-negative subtype) with BM from breast cancer were available for the analysis. Brain metastases free survival differed significantly between breast cancer subtypes. Median BMFS in triple-negative tumours was 14 months (95% CI: 11.34-16.66) compared with 18 months (95% CI: 14.46-21.54) in HER-2-positive tumours (P=0.001) and 34 months (95% CI: 23.71-44.29) in luminal tumours (P=0.001), respectively. In HER-2-positive patients, co-positivity for ER and HER-2 prolonged BMFS (26 vs 15 m; P=0.033); in luminal tumours, co-expression of ER and PgR was not significantly associated with BMFS. Brain metastases free survival in patients with lung metastases was significantly shorter (17 vs 21 months; P=0.014).Conclusion:Brain metastases free survival in triple-negative breast cancer, as well as in HER-2-positive/ER-negative, is significantly shorter compared with HER-2/ER co-positive or luminal tumours, mirroring the aggressiveness of these breast cancer subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
27. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.
- Author
-
Bartsch, R, Berghoff, A, Pluschnig, U, Bago-Horvath, Z, Dubsky, P, Rottenfusser, A, DeVries, C, Rudas, M, Fitzal, F, Dieckmann, K, Mader, R M, Gnant, M, Zielinski, C C, and Steger, G G
- Subjects
HER2 gene ,BREAST cancer patients ,TRASTUZUMAB ,CANCER treatment ,METASTASIS ,BRAIN cancer diagnosis ,CANCER chemotherapy - Abstract
Background:Trastuzumab-based therapy after diagnosis of brain metastases (BM) may improve survival due to prolonged systemic disease control. We investigated whether lapatinib may yield additional survival benefit.Methods:Eighty patients with BM from HER2-positive breast cancer were identified. Karnofsky Performance Score (KPS) of at least 70 was required. We included a control group of 37 patients treated before 2003, when continuation of trastuzumab after diagnosis of BM was not yet recommended. Remainders received either trastuzumab or lapatinib and trastuzumab (either concomitantly or sequentially) with or without chemotherapy.Results:Median overall survival (OS) in patients receiving trastuzumab after diagnosis of BM was 13 months; corresponding numbers were 9 months in patients treated with chemotherapy, and 3 months with radiotherapy alone. Median OS was not reached in the lapatinib group. Addition of lapatinib prolonged OS over trastuzumab alone (P=0.002). After correction for potential confounders, lapatinib therapy remained an independent positive predictor for survival (HR 0.279; P=0.012).Interpretation:This retrospective single-centre study suggests that the introduction of lapatinib improved survival in patients with BM from HER2-positive breast cancer. Patients with KPS 70 may benefit when treated with lapatinib in addition to trastuzumab after completion of local therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
- Author
-
Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, and Belani CP
- Published
- 2011
- Full Text
- View/download PDF
29. Detection of in the Lower Deschutes River Basin, Oregon.
- Author
-
ZIELINSKI, C. M., LORZ, H .V, and BARTHOLOMEW, J. L.
- Subjects
ANADROMOUS fishes ,FISH migration ,DAMS ,SALMON - Abstract
The Deschutes River, located in central Oregon, is a tributary of the Columbia River. The migration of anadromous fish into the upper Deschutes River basin was blocked in the late 1960s by a series of dams constituting the Pelton Round Butte Hydroelectric Project (PRB). Plans to reintroduce anadromous fish runs above the PRB are complicated by concerns over the introduction of (the agent of whirling disease), which is carried into the lower Deschutes River by adult salmon that stray on their return to enzootic regions of the upper Columbia River basin. To develop a fish passage strategy that minimizes the risk of parasite introduction into the upper Deschutes River basin, it is important to determine whether establishment of the life cycle in waters below the PRB has occurred. Fry of susceptible rainbow trout and steelhead (anadromous rainbow trout) were exposed as sentinel fish at various locations in the Deschutes River and its tributaries between 1998 and 2007 to detect . The parasite was found periodically at low prevalence by polymerase chain reaction (PCR) or quantitative PCR assay in fish held at several locations. However, in 2007, the parasite was detected from fish exposed in Trout Creek based on visual examination (pepsin-trypsin digest preparations and histological sections) and molecular methods. This result confirms that is established in the Deschutes River basin below the PRB. Continued introduction of the parasite into the river system below the PRB via stray hatchery summer steelhead was also documented. These findings have implications for managing movement of within the watershed. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
30. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
- Author
-
Wiedermann, Ursula, Wiltschke, C., Jasinska, J., Kundi, M., Zurbriggen, R., Garner-Spitzer, E., Bartsch, R., Steger, G., Pehamberger, H., Scheiner, O., and Zielinski, C.
- Abstract
We have previously shown in mice that vaccination with three Her-2-peptides representing B-cell epitopes of the extracellular domain of Her-2/neu induces Her-2/neu-specific IgG antibodies with strong anti-tumor activity in vitro and in vivo. We have now finalized a phase I clinical trial with an anti-Her-2/neu vaccine-construct of immunopotentiating reconstituted influenza virosomes with the three peptides in patients with metastatic breast cancer (MBC). Ten MBC patients with low protein overexpression of Her-2/neu of MBC (+ or ++ upon immunohistochemistry, FISH negative) and positive hormone receptor status were enrolled in a single center phase I study. The virosomal formulated vaccine, consisting of 10 μg/peptide, was intramuscularly applied three times on days 1, 28, and 56. The primary endpoint of the study, which lasted 12 weeks, was safety, the secondary endpoint immunogenicity. Local erythema at the injection site was the only vaccine-related side effect occurring in four patients. In 8 of 10 patients an increase in peptide-specific antibody titer measured by ELISA was found. Importantly, the induced antibodies were also directed against the native Her-2/neu protein. Cellular immune responses, as measured by in vitro production of IL-2, IFN-γ, and TNF-α of PBMCs showed a marked increase after vaccination in the majority of vaccinees. Notably, the number of CD4+CD25+Foxp3+T regulatory cells, which were significantly increased compared to healthy controls prior to vaccination, was markedly reduced following vaccination. In all, the immunological responses after vaccination indicated that the patients in stage IV of disease were immunocompetent and susceptible to vaccination. The Her-2/neu multipeptide vaccine was safe, well tolerated and effective in overcoming immunological tolerance to Her-2/neu. The induction of anti-Her-2-specific antibodies could result in clinical benefit comparable to passive anti-Her-2 antibody therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
31. CD98hc (SLC3A2), a novel marker in renal cell cancer.
- Author
-
Prager, G. W., Poettler, M., Schmidinger, M., Mazal, P. R., Susani, M., Zielinski, C. C., and Haitel, A.
- Subjects
ANTIGENS ,RENAL cell carcinoma ,GENE targeting ,PROTEIN-tyrosine kinases ,CELL membranes ,CELL differentiation - Abstract
Background In a variety of malignant diseases, molecular targeting represents a therapeutic option, whereby, when compared with chemotherapy, fewer side effects are thought to be expected. Especially in renal cell cancer (RCC), tyrosine kinase-inhibitors have been established as useful and highly effective therapy. However, tyrosine kinase-inhibitors currently approved for RCC treatment lack single molecule specificity and bear a variety of side effects of the gastro-intestinal tract, skin, heart and haematopoietic system. Therefore, the identification of novel cell surface markers is sought, which might lead to novel diagnostic and therapeutic strategies in cancer. Material and methods Paraffin-embedded RCCs from a well characterized tissue bank were immunohistochemically quantified for embryonic transmembrane antigen CD98hc (SLC3A2) expression and semi-quantitative analyses were correlated with subtype or grade of differentiation. Results We found increased CD98hc expression in different types of malign RCCs, among them clear cell (cc)RCC, papillary (p)RCC and chromophobe (ch)RCC, but lack of expression in the benign renal oncocytoma. Thereby, the extent of CD98hc expression directly complies with grade of malignancy. Furthermore, the more malignant type II pRCC significantly higher expressed CD98hc than the less malignant and more differentiated type I pRCC (type II 83·34%, type I 4·76% CD98hc positive, P < 0·00001; n = 51). The established marker for type I pRCC, Cytokreatin 7, showed 95·24% expression in type I and 26·67% expression in type II pRCC ( P < 0·00001, n = 51). Conclusions From these data, we conclude that CD98hc is expressed in RCCs, whereby the extent of expression is likely to correlate directly with grade of malignancy. In pRCCs, CD98hc might represent a novel and reliable marker for type II pRCC. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
32. Treatment of metastatic breast cancer: a historical perspective.
- Author
-
Zielinski, C. C.
- Abstract
Metastatic breast cancer is incurable and treatment decisions are complex. Despite the range of therapeutic agents available and the use of different approaches with these agents, an efficacy plateau had been reached. The development of novel therapies based on a greater understanding of the aetiology of breast cancer has begun to produce unprecedented increases in efficacy. This paper reviews the latest advances in the treatment of metastatic breast cancer, including the established aromatase inhibitors and human epidermal growth factor receptor 2-targeted therapies. The recent introduction of anti-angiogenic therapies, such as bevacizumab, may have even greater impact due to their potential to benefit all breast cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
33. Consensus on the medical treatment of colon cancer.
- Author
-
Kornek, G., Scheithauer, W., Anghel, R., Bodoky, G., Ciardiello, F., Ciuleanu, T., Glynne-Jones, R., Gruenberger, T., Koza, I., Ocvirk, J., Petruzelka, L., Poston, G., Ramadori, G., Schmiegel, W., Segaert, S., Tabernero, J., Zwierzina, H., and Zielinski, C.
- Abstract
PURPOSE: To throw light on some of the issues in the choice of therapy for patients with metastatic colorectal cancer (mCRC) and to provide consensus recommendations on which combination(s) and sequence(s) of systemic therapy to be used in different treatment situations. MATERIAL AND METHODS: An expert panel comprising clinicians from Austria, Belgium, the Czech Republic, Germany, Hungary, Italy, Romania, Slovakia, Slovenia, Spain and the UK with expertise in medical oncology, clinical oncology, surgery and dermatology, and specialist knowledge of the treatment of patients with CRC was convened by the Central European Cooperative Oncology Group (CECOG) in Vienna in 2007. Members were then asked to agree on a consensus statement following a period of discussion at the end of a series of presentations. RESULTS AND CONCLUSIONS: The consensus recommendations for the state-of-the-art treatment of colon cancer arrived at by an "expert panel" of clinicians were that: oral 5-fluorouracil (5-FU) prodrugs or protracted intravenous infusion of the antimetabolite are preferable to bolus administration; all active drugs (fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab, cetuximab) should be used during strategic patient management; after neoadjuvant treatment and consultation of an interdisciplinary team, surgery should be considered for metastatic disease wherever possible and "fit" elderly patients should not be denied the same treatment as younger patients. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
34. Multiyear validation of the NRL-G2S wind fields using infrasound from Yasur.
- Author
-
Antier, K., Le Pichon, A., Vergniolle, S., Zielinski, C., and Lardy, M.
- Published
- 2007
- Full Text
- View/download PDF
35. Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System.
- Author
-
Sagaster, V., Kaufmann, H., Odelga, V., Ackermann, J., Gisslinger, H., Rabitsch, W., Zojer, N., Ludwig, H., Nösslinger, T., Zielinski, C., and Drach, J.
- Subjects
CHROMOSOME abnormalities ,MULTIPLE myeloma ,FLUORESCENCE in situ hybridization ,FLUORESCENCE microscopy ,CHROMOSOMES - Abstract
Little is known about tumor-related prognostic factors, in particular specific chromosomal abnormalities, in young patients with multiple myeloma (MM). We therefore investigated the chromosomal pattern by interphase fluorescence in situ hybridization (chromosomes 13q14, 14q32-translocations, chromosomes associated with hyperdiploidy) in 38 young patients with MM (age <45 yr) and compared the results with those observed in 69 patients with intermediate age (45–70 yr) and 64 elderly patients (age >70 yr). All chromosomal patterns were not significantly different between the three age cohorts. Similarly, standard MM parameters were equally distributed between these MM patient populations. However, survival by the International Staging System (ISS) for MM revealed marked differences between stage I/II (median survival not yet reached) and stage III (23.4 months; P < 0.0003) among young MM patients. A significant survival difference between ISS-stage I/II and ISS-stage III patients was also noted in the intermediate age group (median 65.4 months vs. 24.6 months; P = 0.0009). However, this difference disappeared among elderly MM patients (39.6 months in ISS-stage I/II vs. 32 months in ISS-stage III patients; P = 0.94), but it was unrelated to the cytogenetic pattern. Our results indicate that MM in young patients does not represent a distinct biologic entity, and that short survival of younger MM patients at ISS-stage III is independent of the molecular cytogenetic pattern. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
36. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
- Author
-
Sagaster, V., Ludwig, H., Kaufmann, H., Odelga, V., Zojer, N., Ackermann, J., Küenburg, E., Wieser, R., Zielinski, C., and Drach, J.
- Subjects
MULTIPLE myeloma ,BLOOD plasma ,BLOOD proteins ,FLUORESCENCE microscopy ,B cell lymphoma ,CHROMOSOMES - Abstract
Studies of bortezomib in patients with relapsed multiple myeloma (MM) suggested that bortezomib may be active even in the presence of adverse prognostic factors. We therefore evaluated 62 patients with relapsed/refractory MM who were treated with single-agent bortezomib, and addressed the question whether or not the negative prognostic impact of unfavorable cytogenetic abnormalities may be overcome by bortezomib. By interphase fluorescence in situ hybridization (FISH), a deletion of chromosome 13q14 [del(13q14)] was present in 33 patients (53%). Overall response rates to bortezomib were similar in patients with and without del(13q14) (45 versus 55%; P=0.66), and rates of complete remission (CR) near CR were also not different between the two patient populations (18 versus 14%). Three patients had a t(4;14)(p16;q32) in addition to del(13q14), and all of them had a >50% paraprotein reduction. Median duration of response was 12.3 months in patients with del(13q14) compared with 9.3 months in patients with normal 13q-status (P=0.25), and survival was also not different between the two patient populations. Patients not benefiting from single-agent bortezomib were characterized by the combined presence of a del(13q14) and low serum albumin (median survival 4.6 months). Our results provide evidence for remarkable activity of bortezomib in MM with del(13q14). Patients who do not respond to bortezomib and consecutively have short time to treatment failure and overall survival can be identified by low serum albumin in addition to del(13q14) and should be considered for bortezomib combinations.Leukemia (2007) 21, 164–168. doi:10.1038/sj.leu.2404459; published online 9 November 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
37. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable.
- Author
-
Vogl, U. M., Zehetgruber, H., Dominkus, M., Hejna, M., Zielinski, C. C., Haitel, A., and Schmidinger, M.
- Subjects
RENAL cell carcinoma ,RENAL cancer ,CANCER treatment ,CANCER patients ,IMMUNOREGULATION ,CARCINOGENESIS ,MEDICAL research - Abstract
Prognostic and predictive factors in patients with metastatic renal cell carcinoma (MRCC) have been evaluated from untreated patients or patients on several different treatment approaches. The aim of this analysis was to define prognostic and predictive factors in patients treated uniformly with a low-dose outpatient cytokine combination. The relationship between patient-, tumour-, and treatment-related factors was analysed in 99 patients with MRCC. These features were first examined in univariate analyses, then a stepwise modelling approach based on Cox regression was used to form a multivariate model. Nuclear grade, metastasectomy – even incomplete – C-reactive protein and lactate dehydrogenase were identified as independent prognostic factors for survival. Patients assigned to three different risk groups had statistically significant survival differences (30, 22 and 6 months, respectively). A total of 43.4% had undergone metastasectomy, mostly incomplete. Risk group affiliation was correlated with response to treatment. Our findings strongly suggest the consideration of metastasectomy in the management of patients with metastatic renal cell cancer undergoing either immunotherapy or targeted treatment.British Journal of Cancer (2006) 95, 691–698. doi:10.1038/sj.bjc.6603327 www.bjcancer.com Published online 29 August 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
38. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression.
- Author
-
Bilban, M., Heintel, D., Scharl, T., Woelfel, T., Auer, M. M., Porpaczy, E., Kainz, B., Kröber, A., Carey, V. J., Shehata, M., Zielinski, C., Pickl, W., Stilgenbauer, S., Gaiger, A., Wagner, O., Jäger, U., Kröber, A, Jäger, U, and German CLL Study Group
- Subjects
CHRONIC lymphocytic leukemia ,LIPOPROTEIN lipase ,GENE expression ,DYSTROPHIN ,DENDRITIC cells ,ANTIGEN presenting cells - Abstract
Lipoprotein lipase (LPL) is a prognostic marker in B-cell chronic lymphocytic leukemia (B-CLL) related to immunoglobulin V(H) gene (IgV(H))mutational status. We determined gene expression profiles using Affymetrix U133A GeneChips in two groups of B-CLLs selected for either high ('LPL+', n=10) or low ('LPL-', n=10) LPL mRNA expression. Selected genes were verified by real-time PCR in an extended patient cohort (n=42). A total of 111 genes discriminated LPL+ from LPL- B-CLLs. Of these, the top three genes associated with time to first treatment were Septin10, DMD and Gravin (P=0.01). The relationship of LPL+ and LPL- B-CLL gene expression signatures to 52 tissues was statistically analyzed. The LPL+ B-CLL expression signature, represented by 64 genes was significantly related to fat, muscle and PB dendritic cells (P<0.001). Exploration of microarray data to define functional alterations related to the biology of LPL+ CLL identified two functional modules, fatty acid degradation and MTA3 signaling, as being altered with higher statistical significance. Our data show that LPL+ B-CLL cells have not only acquired gene expression changes in fat and muscle-associated genes but also in functional pathways related to fatty acid degradation and signaling which may ultimately influence CLL biology and clinical outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
39. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab.
- Author
-
Zeitlinger, M. A., Schmidinger, M., Zielinski, C. C., Chott, A., and Raderer, M.
- Subjects
T cells ,LYMPHOCYTES ,RETICULOENDOTHELIAL granulomas ,DRUG therapy ,LYMPHOMAS ,ANTINEOPLASTIC agents - Abstract
Lymphoepitheloid cell lymphoma (Lennert's lymphoma) is a rare malignant disease usually affecting patients at advanced age. Although classified as a “low-grade” lymphoma in the past, the clinical course is highly unfavorable and currently available chemotherapeutic regimens have given disappointing results. We present the case of a 74-year-old male suffering from disseminated Lennert's lymphoma. The patient underwent standard treatment approaches including chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP); fludarabin and cyclophosphamide; and ifosfamide, carboplatin and etoposide (ICE). Due to progressive disease with all these regimens, chemotherapy was discontinued. As cells stained highly positive for CD52, immunotherapy with alemtuzumab (Campath-1H) was started using a standard dosing regime of 30?mg every third day. Although the patient received prophylactic anti-infective medication, leucocytopenia with reactivation of cytomegalovirus (CMV) infection was observed and the administration of alemtuzumab had to be stopped temporarily. Re-assessment of disease 5 weeks after the start of alemtuzumab disclosed a significant reduction of all thoracic and abdominal lesions, and therapy with alemtuzumab was continued after normalization of the number of CMV copies and is currently ongoing. Our observations indicate clinical activity of alemtuzumab in the treatment of Lennert's lymphoma, including even bulky nodal disease, particularly for patients who have failed conventional therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
40. Effective Treatment of Indolent Non-Hodgkin’s Lymphomas with Mitoxantrone, Chlorambucil and Prednisone.
- Author
-
Wöhrer, S., Raderer, M., Kaufmann, H., Hejna, M., Chott, A., Zielinski, C., and Drach, J.
- Published
- 2005
- Full Text
- View/download PDF
41. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.
- Author
-
Kaufmann, H, Ackermann, J, Baldia, C, Nösslinger, T, Wieser, R, Seidl, S, Sagaster, V, Gisslinger, H, Jäger, U, Pfeilstöcker, M, Zielinski, C, and Drach, J
- Subjects
MULTIPLE myeloma ,MONOCLONAL gammopathies ,MOLECULAR genetics ,CHROMOSOMAL translocation ,PLASMA cells - Abstract
Molecular and genetic events associated with the transition from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) are still poorly characterized. We investigated serial bone marrow specimens from 11 patients with MGUS who eventually progressed to MM (MM post-MGUS) by interphase fluorescence in situ hybridization for immunoglobulin heavy-chain gene (IgH) translocations and chromosome 13q deletions (del(13q)). In nine patients, IgH translocations were present both in MGUS and MM post-MGUS plasma cells, including three t(11;14)(q13;q32) and one t(4;14)(p16;q32), which was observed already 92 months prior to MM. Similarly, all five MM patients with del(13q) had this aberration already at the MGUS stage. Two patients without IgH translocation and del(13q) had chromosomal gains suggesting hyperdiploidy, but IgH translocations and/or del(13q) did not emerge at MM post-MGUS. IgH translocations and del(13q) are early genetic events in monoclonal gammopathies, suggesting that additional events are required for the transition from stable MGUS to progressive MM.Leukemia (2004) 18, 1879-1882. doi:10.1038/sj.leu.2403518 Published online 23 September 2004 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
42. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.
- Author
-
Hudelist, G, Köstler, W J, Attems, J, Czerwenka, K, Müller, R, Manavi, M, Steger, G G, Kubista, E, Zielinski, C C, and Singer, C F
- Abstract
Proteolytic cleavage of the Her-2/neu extracellular domain (ECD) has been shown to initiate receptor phosphorylation representing Her-2/neu activation in vitro. The present investigation was performed to evaluate the clinical relevance of ECD cleavage for Her-2/neu activation and the consequences of active intracellular Her-2/neu signalling reflected by tyrosine kinase phosphorylation in patients treated with the anti-Her-2/neu antibody trastuzumab. Sera from 62 patients receiving trastuzumab-based treatment for Her-2/neu overexpressing metastatic breast cancer were assessed for pretreatment ECD levels using an enzyme-linked immunosorbent assay. In parallel, Her-2/neu activation status of tumour specimens was assessed by immunohistochemistry using a Her-2/neu phosphorylation state specific antibody (PN2A) and correlated with the patients' ECD levels and clinical course of disease. Serum ECD levels were significantly higher in 15 (24%) patients with tumours exhibiting activated Her-2/neu as compared to those without detectable Her-2/neu phosphorylation (median 148.2 vs 28.5 ng ml(-1), P=0.010). Whereas response rate only showed a trend to be higher in patients with Her-2/neu-phosphorylated breast cancer (47 vs 34%, P=0.197), both uni- and multivariate analyses revealed that the median progression-free survival under trastuzumab-based treatment was significantly longer in patients with Her-2/neu-phosphorylated breast cancer-11.7 (95% CI 5.2-18.3) months-when compared to the progression-free survival of 4.5 (95% CI 3.4-5.6) months observed in patients with tumours lacking phosphorylated Her-2/neu (P=0.001). Proteolytic cleavage of the ECD represents a biologically relevant ligand-independent mechanism of Her-2/neu activation in vivo. The influence of Her-2/neu activation status upon the outcome of trastuzumab-based therapies merits further investigation in larger prospective trials. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
43. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status.
- Author
-
Brodowicz, T, Kandioler, D, Tomek, S, Ludwig, C, Rudas, M, Kunstfeld, R, Koestler, W, Hejna, M, Budinsky, A, Wiltschke, C, and Zielinski, C C
- Subjects
BREAST cancer ,CANCER cells ,IMMUNOGLOBULINS - Abstract
Anti-Her-2/neu antibody is known to induce apoptosis in HER-2/neu overexpressing breast cancer cells. However, exact regulatory mechanisms mediating and controlling this phenomenon are still unknown. In the present study, we have investigated the effect of anti-Her-2/neu antibody on apoptosis of HER-2/neu overexpressing human breast cancer cell lines SK-BR-3, HTB-24, HTB-25, HTB-27, HTB-128, HTB-130 and HTB-131 in relation to p53 genotype and bcl-2 status. SK-BR-3, HTB-24, HTB-128 and HTB-130 cells exhibited mutant p53, whereas wild type p53 was found in HTB-25, HTB-27 and HTB-131 cells. All seven cell lines weakly expressed bcl-2 protein (10-20%). Anti-Her-2/neu antibody, irrespective of p53 and bcl-2 status, induced apoptosis in all 7 cell lines dose- and time-dependently and correlated with Her-2/neu overexpression. In addition, incubation of cell lines with anti-Her-2/neu antibody did not alter p53 or bcl-2 expression. Anti-HER-2/neu antibody did not induce apoptosis in HER-2/neu negative HBL-100 and HTB-132 cell lines. Our results indicate that within the panel of tested breast cancer cell lines, anti-Her-2/neu antibody-induced apoptosis was independent from the presence of intact p53. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
44. Difference in patient's acceptance of early versus late initiation of psychosocial support in breast cancer.
- Author
-
Scholten, Christine, Weinländer, Georg, Krainer, Michael, Frischenschlager, Oskar, Zielinski, Christoph, Scholten, C, Weinländer, G, Krainer, M, Frischenschlager, O, and Zielinski, C C
- Abstract
The present study was performed to assess the difference in acceptance of psychosocial counseling and resulting benefits between patients with breast cancer with early or late onset. In a prospective randomized controlled study conducted over 6 months, 41 women with a new diagnosis of early breast cancer (group 1) and 43 patients with advanced breast cancer (group 2) received individually tailored psychosocial support and were compared against controls. This therapy was free of charge, and the duration of support was determined by the patients' wishes and needs. Among the patients with new onset of disease acceptance of the psychosocial counseling was high, and these patients experienced significant improvements in their quality of life. In contrast, acceptance of psychosocial counseling was low in the advanced breast cancer group and the therapy did not improve quality of life over the observation period of 6 months. Early psychosocial support in patients with breast cancer meets with a high acceptance rate and improves quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
45. Delayed Superficialization of Brachiobasilic Fistula: Technique and Initial Experience.
- Author
-
Zielinski, C. M. V., Mittal, Sumeet K., Anderson, Pete, Cummings, Judd, Fenton, Steve, Reiland-Smith, Julian, Frock, J. T., and Dunlay, R. W.
- Subjects
ARTERIAL catheterization ,ARTERIOVENOUS fistula - Abstract
Hypothesis: Angioaccess procedures for dialysis have varied patency rates with frequent need for intervention. A superficialized arteriovenous brachiobasilic fistula created as a 2-step procedure will have good long-term patency with minimal complication. Design: Retrospective medical record review and patient interview. Setting: Tertiary referral university hospital. Patients: Twelve patients who underwent delayed superficialization of brachiobasilic fistula from September 1994 to April 2000. Main Outcome Measures: Patency of fistula for dialysis, and major and minor complications, including revisions. Results: Delayed superficialization of brachiobasilic fistula was performed in 12 patients. Fistulas have been used for a mean duration of 22.4 months (range, 10-59 months). Two patients required alternate access owing to thrombosis of brachiobasilic fistula. Conclusions: The delayed superficialized brachiobasilic arteriovenous fistula has a good initial patency rate with minimal complications. It should be considered early in patients if radiocephalic fistula is unavailable. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
46. Verapamil decreases accumulation of 99Tcm-MIBI and 99Tcm-tetrofosmin in human breast cancer and soft tissue sarcoma cell lines.
- Author
-
RODRIGUES, M., KALINOWSKA, W., ZIELINSKI, C., and SINZINGER, H.
- Published
- 2001
- Full Text
- View/download PDF
47. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group.
- Author
-
Wagner, T M U, Möslinger, R, Langbauer, G, Ahner, R, Fleischmann, E, Auterith, A, Friedmann, A, Helbich, T, Zielinski, C, Pittermann, E, Seifert, M, Oefner, P, and Wagner, T M
- Subjects
GENETIC counseling ,MENTAL depression ,MASTECTOMY ,BREAST tumor prevention ,OVARIECTOMY ,BREAST tumors ,COMPARATIVE studies ,DISEASE susceptibility ,GENEALOGY ,GENETIC techniques ,HEALTH attitudes ,RESEARCH methodology ,MEDICAL cooperation ,OVARIAN tumors ,QUALITY of life ,RESEARCH ,RESEARCH funding ,EVALUATION research ,BRCA genes ,PSYCHOLOGY ,PREVENTION - Abstract
The intent of this study was to evaluate the effect that an awareness of being a BRCA1 or BRCA2 mutation carrier has on the attitude towards prophylactic surgery and on developing depression symptoms. Thirty-five families were selected on the basis of previously detected BRCA1 or 2 mutations and 90 family members were given the appropriate questionnaires. Prophylactic mastectomy (PM) was considered by 21% of the Austrian mutation carriers (29% affected and 8% non-affected carriers). The majority of affected and non-affected carriers expected PM to impair the quality of their life. Fifty per cent would undergo prophylactic oophorectomy (53% affected and 46% non-affected carriers). The self-rating depression scale indicated that following mutation result disclosure the depression scores of carriers decreased (40 baseline vs 38 after result disclosure, P = 0.3), whereas, for non-carriers, scores increased (36 baseline vs 40 after result disclosure, P = 0.05). We conclude that information about carrier status is not associated with increased depression symptoms in mutation carriers. In non-carriers, depression scores increased slightly, probably reflecting survivor guilt. The option of having PM was associated with a negative impact on the quality of life and was declined by the majority of Austrian mutation carriers. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
48. Bildgebung als Teil des klinischen Tumorstagings.
- Author
-
Brodowicz, T. and Zielinski, C. C.
- Abstract
Copyright of Der Radiologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 1999
- Full Text
- View/download PDF
49. Fortschritte in der Hormontherapie des Mammakarzinoms.
- Author
-
Brodowicz, T., Wiltschke, C., and Zielinski, C.
- Published
- 1998
- Full Text
- View/download PDF
50. Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-α and retinoids.
- Author
-
Brodowicz, T, Wiltschke, C, Kandioler-Eckersberger, D, Grunt, T W, Rudas, M, Schneider, S M, Hejna, M, Budinsky, A, and Zielinski, C C
- Subjects
APOPTOSIS ,TUMOR growth ,SARCOMA ,INTERFERONS ,RETINOIDS - Abstract
Uncontrolled proliferation and a defect of apoptosis constitute crucial elements in the development and progression of tumours. Among many other biological response modifiers known to influence these mechanisms, the efficacy of retinoids and interferons in the treatment of various malignant entities is currently matter of discussion. In the present study, we have investigated the effects of 9-cis-retinoic acid (9cRA), 13-cis-retinoic acid (13cRA), all-trans-retinoic acid (tRA) and interferon-α on proliferation and apoptosis of human soft tissue sarcoma (STS) cell lines HTB-82 (rhabdomyosarcoma), HTB-91 (fibrosarcoma), HTB-92 (liposarcoma), HTB-93 (synovial sarcoma) and HTB-94 (chondrosarcoma) in relation to p53 genotype as well as p53 expression. HTB-91, HTB-92 and HTB-94 STS cells exhibited mutant p53, whereas wild-type p53 was found in HTB-93 STS cells, and a normal p53 status in HTB-82 STS cells, carrying a silent point mutation only. Interferon-α, irrespective of p53 status, inhibited the proliferation of all five cell lines dose- and time-dependently. Similarly, 9cRA, 13cRA and tRA decreased the proliferation of HTB-82 and HTB-93 STS cells, whereas the proliferation of p53-mutated HTB-91, HTB-92 and HTB-94 STS cells remained unchanged. Furthermore, only 9cRA and tRA were capable of inducing apoptosis in HTB-82 and HTB-93 STS cells, whereas HTB-91, HTB-92 and HTB-94 STS cells did not undergo apoptosis under the influence of 9cRA or tRA. Retinoic acid receptor (RAR)-α and RAR-β mRNA were not detectable by Northern blot analysis in the five STS cell lines, whereas mRNA for the universal retinoic acid receptor, RAR-γ, was expressed in all STS cell lines indicating that retinoid resistance was not associated with a lack of RAR expression. Apoptosis was not induced by interferon-α or 13cRA in any of the five STS cell lines tested. Our results indicate that within the panel of tested STS cell lines, inhibition of proliferation... [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.